The medical device industry has an ethylene oxide problem, and it's only getting worse.
For decades, roughly half of all sterile medical devices in the United States—surgical kits, catheters, implants—have been treated with the colorless gas before ever reaching an operating room. Effective, yes. But ethylene oxide is also a known carcinogen, and the EPA has been tightening the regulatory vise with each passing year. In March 2024, the agency finalized what it called its "strongest measures" yet: sweeping new rules designed to slash emissions from commercial sterilization facilities across the country.
That regulatory squeeze has opened a window. And a small Michigan company called SterileState is betting it can wedge itself through.
According to a Form D/A filed with the SEC on June 22, 2026, SterileState closed a $10.8 million funding round from 69 investors—a broad, angel-heavy roster that suggests the company cast a wide net rather than landing a big institutional check. The raise positions the Grand Rapids-based startup to commercialize what it describes as a nitric oxide-based sterilization technology that could, in theory, let device manufacturers sidestep ethylene oxide entirely.
It's an audacious pitch. Whether the FDA—and the market—will buy it is another matter.
From Wound Care to War on EtO
SterileState didn't start life as a sterilization company.
Dr. Megan Frost, a chemist with a PhD from the University of Michigan, founded the venture back in 2013 under the name FM Wound Care. At the time, she was a professor at Michigan Technological University, deep in academic research on nitric oxide-releasing polymers and their potential to accelerate healing. She'd spent a decade in academia. The wound care angle seemed like the obvious path.
Except Frost spotted something bigger—a way to weaponize her polymer chemistry not for wounds, but for the multi-billion-dollar sterilization bottleneck choking device manufacturers. The company pivoted. Hard.
By the time CEO Kurt Yockey came aboard to lead commercialization, SterileState had relocated from Hancock—a small town in Michigan's Upper Peninsula—to Grand Rapids, where manufacturing infrastructure and a deeper talent pool made scaling more plausible. Yockey, a medical device veteran with a legal background, brought the operational discipline. Frost brought the science.
Together, they're now selling investors on what they've branded "SterileState•78."
Four Hours Versus Four Weeks
Here's how it works, at least in principle.
The company embeds nitric oxide in a small polymer device that gets tucked inside the sealed packaging alongside the medical device—before the package is closed. Once sealed, the polymer releases nitric oxide gas, which sterilizes the contents in roughly four hours, according to a presentation Yockey delivered at The [PACK]out conference in May 2023.
Compare that to the traditional ethylene oxide dance: ship the device to an off-site sterilization facility, wait days or sometimes weeks for processing, then endure additional aeration time to clear toxic residues before the product can move. "Manufacture, package & sterilize, ship," SterileState's website promises. Cut out the middleman.
By early July 2025, the company claimed to have tested more than 60 medical devices from nearly 40 manufacturers, with no material degradation reported, Yockey told Healthcare Packaging. Among the companies said to be evaluating the technology: SCHOTT Pharma. But no formal partnerships or customer contracts have been announced, and it's unclear how far any of those conversations have progressed.
The Regulatory Question Mark
And then there's the FDA.
SterileState has no official approval timeline. In 2023, Yockey acknowledged the team was "before the FDA," working through what he described as the regulatory pathway for an entirely new sterilization modality. The company's website currently states that "regulatory approval is in process" for certain use cases—but offers nothing in the way of specifics. No target dates. No indication of which pathway the company is pursuing or how far along it might be.
That vagueness isn't unusual for a novel sterilization method. The FDA has recognized alternatives like vaporized hydrogen peroxide and continues to evaluate new modalities through initiatives such as its 2019 Innovation Challenge. But each new approach must prove efficacy, material compatibility, and safety across a dizzying range of device types. It's a slow, expensive process. And until you clear it, you're selling a promise, not a product.
Still, the market pressure is real. Noxilizer, another upstart using nitrogen dioxide gas, pulled in $30 million in growth financing last September to expand capacity. Money is flowing toward anything that can credibly claim to replace ethylene oxide.
Whether SterileState can get there first—or at all—remains an open question.
Sixty-Nine Investors, No Whale
The SEC filing offers a few clues about the round's composition, though not many.
SterileState raised the $10.78 million under Rule 506(b), a private placement exemption that prohibits the company from publicly disclosing investor names. The first sale closed on January 7, 2025, when the company had 30 backers. By June 2026, that number had ballooned to 69.
That kind of sprawl—more than doubling the investor count over 18 months—suggests a syndicate of angels, family offices, or small funds rather than a single lead institution writing a big check. The total offering size is listed at $13 million, leaving roughly $2.2 million still on the table. No sales commissions were paid, and zero proceeds went to related parties, according to the filing.
SterileState did not respond to requests for comment on investor composition or how it plans to deploy the capital.
The Long Game
CEO Yockey is scheduled to speak at the Sterilization Summit USA 2026, part of the company's broader effort to position nitric oxide alongside vaporized hydrogen peroxide, nitrogen dioxide, and other contenders in the post-ethylene oxide sweepstakes.
SterileState's website hints at grander ambitions—pharmaceutical packaging, wound care (a callback to the company's origins), food safety, even agriculture. But those remain speculative until the core technology clears both regulatory muster and commercial validation in medical devices.
For now, the company has runway. It has a tested technology, at least in lab and pilot settings. And it has a regulatory tailwind, courtesy of an EPA that shows no signs of easing pressure on ethylene oxide emitters.
Whether that's enough to navigate the FDA's labyrinth and displace entrenched sterilization infrastructure—decades-old facilities, established supply chains, risk-averse procurement departments—is the $10.8 million question. Perhaps more, if SterileState fills out the rest of that $13 million round.
In an industry where the status quo has enormous inertia, betting on disruption is always a gamble. SterileState is placing its chips. Now it has to prove the technology works, persuade regulators it's safe, and convince manufacturers to rip up their sterilization playbooks.
No small task. But then again, neither is replacing a carcinogen that's been the industry standard for half a century.
